4d Molecular Therapeutics, INC Schedule 13G passive stakes

RA Capital Management and its principals have filed an amended Schedule 13G disclosing a 9.9% beneficial ownership stake in 4D Molecular Therapeutics, Inc.

State Street Corporation has reported beneficial ownership of 5.3% of 4D Molecular Therapeutics' common stock as of March 31, 2026.

Janus Henderson Group plc has reported a beneficial ownership of 10.3% of 4D Molecular Therapeutics, Inc. common stock as of March 31, 2026.

The Vanguard Group filed an amended Schedule 13G, indicating a 0% beneficial ownership in 4D Molecular Therapeutics Inc. following an internal realignment.

Janus Henderson Group plc has reported a beneficial ownership of 8.1% in 4D Molecular Therapeutics, Inc., holding 4,635,875 common shares.

Goldman Sachs Group and its affiliate Goldman Sachs & Co. LLC have reported a 7.5% beneficial ownership in 4D Molecular Therapeutics, Inc. common stock.

Novo Holdings A/S has reported a 6.8% beneficial ownership stake in 4D Molecular Therapeutics, Inc., holding 3,175,000 shares of common stock.

BlackRock, Inc. has reported a 6.6% beneficial ownership in 4D Molecular Therapeutics, Inc. common stock as of September 30, 2025.

Venrock Healthcare Capital Partners and affiliated entities have filed an amended Schedule 13G, disclosing a continued beneficial ownership of 1.5% in 4D Molecular Therapeutics, Inc. as of March 31, 2025.

A group of investment entities led by Biotechnology Value Fund, L.P. and Mark N. Lampert has disclosed a combined beneficial ownership of 9.99% in 4D Molecular Therapeutics, Inc. common stock as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 7.8% of 4D Molecular Therapeutics Inc.'s Common Stock as of March 31, 2025.

RA Capital Management and its affiliated entities have filed an amended Schedule 13G, reaffirming their beneficial ownership of 9.9% of 4D Molecular Therapeutics, Inc.'s common stock as of December 31, 2024.

Venrock Healthcare Capital Partners and its affiliated entities have filed an amendment to their Schedule 13G, confirming a continued 6.4% beneficial ownership in 4D Molecular Therapeutics, Inc. as of December 31, 2024.

A group of investment funds and entities managed by Biotechnology Value Fund, including Mark N. Lampert, have reported a combined beneficial ownership of 9.99% in 4D Molecular Therapeutics, Inc. as of December 31, 2024.

Janus Henderson Group plc has filed an Amendment No. 4 to Schedule 13G, reporting a beneficial ownership of 4.9% in 4D Molecular Therapeutics, Inc. as of December 31, 2024.

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, filed an amended Schedule 13G disclosing a continued passive beneficial ownership of 1.32% in 4D Molecular Therapeutics Inc.'s common stock as of December 31, 2024.

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have reported a 9.6% beneficial ownership stake in 4D Molecular Therapeutics, Inc. as of December 31, 2024, through an amended Schedule 13G filing.